HepaTx and Mayo Clinic Collaborate to Accelerate Cell Therapy for Liver Disease to Clinical Trials
HepaTx, a biotechnology company focused on regenerative medicine, has announced an exciting collaboration with the Mayo Clinic to advance its innovative cell therapy technology into clinical trials. This partnership, revealed on September 10, 2024, aims to offer new therapeutic approaches for liver diseases, initially targeting alcohol-related hepatitis. The collaboration leverages Mayo Clinic’s clinical research infrastructure […]
Immorta Bio Inc. Announces Breakthrough in Liver Failure Treatment with Stem Cell Technology
Immorta Bio Inc., a company focused on longevity and regenerative medicine, has announced a significant breakthrough in the treatment of liver failure. The company is developing personalized stem cell technologies that show great promise in combating various diseases of aging. Immorta Bio’s research pipeline includes Personalized Regenerative Cells (PRCs), Personalized Mesenchymal Stem Cells (pMSCs), and […]
Stem Cell Therapy for Liver Disease: A New Horizon in Medical Treatment
Ever wondered if there’s a magic bullet for liver disease? While magic might be off the table, the realm of modern medicine brings us something almost as spellbinding: stem cell therapy. This cutting-edge treatment option is emerging as a beacon of hope for those battling the relentless waves of liver conditions. But before we dive into […]
How Hepatic Stem Cells Contribute to Liver Function Restoration
Welcome to our deep dive into the fascinating world of hepatic stem cells and their role in liver function restoration. If you’ve ever wondered about the incredible regenerative abilities of the liver, you’re in the right place. We’re going to explore the science behind how stem cells contribute to liver regeneration, and why this is […]
Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company’s ImmCelz® Product
PHOENIX, April 20, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced progress in developing a reproducible clinical grade product of ImmCelz®. Multiple clinical experiments were performed in which […]